Related references
Note: Only part of the references are listed.5-HTTLPR polymorphism, mood disorders and MDMA use in a 3-year follow-up study
Rocio Martin-Santos et al.
ADDICTION BIOLOGY (2010)
Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance Part I
Shu-Feng Zhou
CLINICAL PHARMACOKINETICS (2009)
Neurotoxic Thioether Adducts of 3,4-Methylenedioxymethamphetamine Identified in Human Urine After Ecstasy Ingestion
Ximena Perfetti et al.
DRUG METABOLISM AND DISPOSITION (2009)
Effects of Dose and Route of Administration on Pharmacokinetics of (±)-3,4-Methylenedioxymethamphetamine in the Rat
Michael H. Baumann et al.
DRUG METABOLISM AND DISPOSITION (2009)
Molecular and Cellular Mechanisms of Ecstasy-Induced Neurotoxicity: An Overview
Joao Paulo Capela et al.
MOLECULAR NEUROBIOLOGY (2009)
Executive Working Memory Deficits in Abstinent Ecstasy/MDMA Users: A Critical Review
Philip N. Murphy et al.
NEUROPSYCHOBIOLOGY (2009)
The Role of Human Hepatic Cytochrome P450 Isozymes in the Metabolism of Racemic 3,4-Methylenedioxy-Methamphetamine and Its Enantiomers
Markus R. Meyer et al.
DRUG METABOLISM AND DISPOSITION (2008)
The consequences of 3.4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans
Brian O'Mathuna et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2008)
Actions of 3,4-methylenedioxymethamphetamine (MDMA) on cerebral dopaminergic, serotonergic and cholinergic neurons
Gary A. Gudelsky et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2008)
Plasma pharmacokinetics of 3.4-methylenedioxymethamphetamine after controlled oral administration to young adults
Erin A. Kolbrich et al.
THERAPEUTIC DRUG MONITORING (2008)
Gender differences in pharmacological response
Gail D. Anderson
EPILEPSY IN WOMEN: THE SCIENTIFIC BASIS FOR CLINICAL MANAGEMENT (2008)
Neurotoxicity mechanisms of thioether ecstasy metabolites
J. P. Capela et al.
NEUROSCIENCE (2007)
Gender differences in drug responses
Flavia Franconi et al.
PHARMACOLOGICAL RESEARCH (2007)
Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping
D. Frank et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes
Julia Kirchheiner et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2007)
Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA
Jiansong Yang et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2006)
Problematic versus non-problematic ecstasy/MDMA use: the influence of drug usage patterns and pre-existing psychiatric factors
K. Soar et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2006)
Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan:: sources of variability and predictors of adverse effects in 419 healthy subjects
C Funck-Brentano et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Substrate specific metabolism by polymorphic cytochrome P450 2D6 alleles
A Bogni et al.
TOXICOLOGY IN VITRO (2005)
MDMA (ecstasy) pharmacokinetics in a CYP2D6 poor metaboliser and in nine CYP2D6 extensive metabolisers
R de la Torre et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans - Use of paroxetine as a metabolic inhibitor probe
M Segura et al.
CLINICAL PHARMACOKINETICS (2005)
Repeated doses administration of MDMA in humans:: pharmacological effects and pharmacokinetics
M Farré et al.
PSYCHOPHARMACOLOGY (2004)
The role of metabolism in 3,4-(±)-methylenedioxyamphetamine and 3.4-(±)-methylenedioxymethamphetamine (ecstasy) toxicity
TJ Monks et al.
THERAPEUTIC DRUG MONITORING (2004)
Human pharmacology of MDMA -: Pharmacokinetics, metabolism, and disposition
R de la Torre et al.
THERAPEUTIC DRUG MONITORING (2004)
Neurotoxicity of MDMA (ecstasy):: the limitations of scaling from animals to humans
R de la Torre et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2004)
Assessment of en vivo CYP2D6 activiy:: Differential sensitivity of commonly used probas to urine pH
M Özdemir et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Diagnosing comorbid psychiatric disorders in substance abusers:: Validity of the Spanish versions of the psychiatric research interview for substance and mental disorders and the structured clinical interview for DSM-IV
M Torrens et al.
AMERICAN JOURNAL OF PSYCHIATRY (2004)
Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry
UM Zanger et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2004)
Clinical pharmacokinetics of amfetamine and related substances - Monitoring in conventional and non-conventional matrices
R de la Torre et al.
CLINICAL PHARMACOKINETICS (2004)
Is ecstasy MDMA? A review of the proportion of ecstasy tablets containing MDMA, their dosage levels, and the changing perceptions of purity
AC Parrott
PSYCHOPHARMACOLOGY (2004)
Synthesis, in vitro formation, and behavioural effects of glutathione regioisomers of alpha-methyldopamine with relevance to MDA and MDMA (ecstasy)
N Easton et al.
BRAIN RESEARCH (2003)
Drug addiction
J Camí et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Multiple toxicity from 3,4-methylenedioxymethamphetamine (Ecstasy)
SL Greene et al.
AMERICAN JOURNAL OF EMERGENCY MEDICINE (2003)
The influence of sex on pharmacokinetics
JB Schwartz
CLINICAL PHARMACOKINETICS (2003)
CYP2D6 deficiency, a factor in ecstasy related deaths?
TC Gilhooly et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2002)
Determination of MDMA and its metabolites in blood and urine by gas chromatography-mass spectrometry and analysis of enantiomers by capillary electrophoresis
N Pizarro et al.
JOURNAL OF ANALYTICAL TOXICOLOGY (2002)
Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research
AC Parrott
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL (2001)
3,4-dihydroxymethamphetamine (HHMA).: A major in vivo 3,4-methylenedioxymethamphetamine (MDMA) metabolite in humans
M Segura et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2001)
Lack of gender differences and large intrasubject variability in cytochrome P450 activity measured by phenotyping with dextromethorphan
JS McCune et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2001)
In-vivo indices of CYP2D6 activity:: comparison of dextromethorphan metabolic ratios in 4-h urine and 3-h plasma
J Chládek et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2000)
Effect of gender, sex hormones, time variables and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates
L Labbé et al.
PHARMACOGENETICS (2000)
Identification of the human cytochromes P450 involved in the oxidative metabolism of Ecstasy-related designer drugs
KP Kreth et al.
BIOCHEMICAL PHARMACOLOGY (2000)
Non-linear pharmacokinetics of MDMA ('ecstasy') in humans
R de la Torre et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2000)
Share Paper
